6.48
전일 마감가:
$5.95
열려 있는:
$6.11
하루 거래량:
168.41K
Relative Volume:
0.68
시가총액:
$235.18M
수익:
$16.10M
순이익/손실:
$-42.57M
주가수익비율:
-4.5948
EPS:
-1.4103
순현금흐름:
$-38.53M
1주 성능:
+25.83%
1개월 성능:
-14.85%
6개월 성능:
+32.52%
1년 성능:
+11.34%
프로파운드 메디컬 Stock (PROF) Company Profile
명칭
Profound Medical Corp
전화
647-476-1350
주소
2400 SKYMARK AVENUE, UNIT 6, MISSISSAUGA, ON
Compare PROF vs ABT, SYK, MDT, BSX, EW
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
|
PROF
Profound Medical Corp
|
6.48 | 215.95M | 16.10M | -42.57M | -38.53M | -1.4103 |
|
ABT
Abbott Laboratories
|
102.67 | 177.03B | 44.33B | 6.50B | 7.40B | 3.717 |
|
SYK
Stryker Corp
|
328.59 | 124.89B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
86.65 | 110.08B | 35.48B | 4.64B | 5.41B | 3.582 |
|
BSX
Boston Scientific Corp
|
62.75 | 93.53B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
80.08 | 45.84B | 6.07B | 1.06B | 1.34B | 1.8063 |
프로파운드 메디컬 Stock (PROF) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-23 | 개시 | Lake Street | Buy |
| 2024-07-16 | 업그레이드 | Stifel | Hold → Buy |
| 2023-11-28 | 개시 | Stifel | Hold |
| 2023-08-04 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2023-03-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2020-09-15 | 개시 | Jefferies | Buy |
모두보기
프로파운드 메디컬 주식(PROF)의 최신 뉴스
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure Milestone - marketscreener.com
If You Invested $1,000 in Profound Med Corp (PROF) - Stock Titan
Profound Medical (NASDAQ:PROF) Trading Down 1.7%Time to Sell? - MarketBeat
Profound Medical (TSE:PRN) Stock Price Down 2.6%Time to Sell? - MarketBeat
Income Plays: Is Profound Medical Corp showing insider buyingStop Loss & AI Based Buy/Sell Signal Reports - baoquankhu1.vn
Profound Medical Touts Positive Trial Results for MRI-Guided TULSA Procedure - Medical Product Outsourcing
Profound Medical Marks Key TULSA Milestone as Texas Prostate Tops 100 Procedures - TipRanks
Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure™ Milestone - The Manila Times
Dallas prostate center says Medicare shift lifted TULSA cases 500% - Stock Titan
Profound Medical (PROF) Surges 13.0%: Is This an Indication of Further Gains? - Yahoo Finance
Q2 2025 Profound Medical Corp Earnings Call Transcript - gurufocus.com
Trading Action: How does Profound Medical Corp perform in inflationary periodsWeekly Trade Recap & Low Drawdown Momentum Trade Ideas - baoquankhu1.vn
Dip Buying: Is Profound Medical Corp showing insider buying2026 Review & Daily Stock Momentum Reports - baoquankhu1.vn
Precision Trading with Profound Medical Corp. (PROF) Risk Zones - news.stocktradersdaily.com
Top 3 Health Care Stocks That Are Set To Fly In March - Benzinga
Profound Medical stock rating reiterated by Raymond James on trial data - Investing.com India
Returns Recap: Can Profound Medical Corp sustain its profitability2026 Macro Moves & Fast Momentum Stock Entry Tips - baoquankhu1.vn
Profound Medical reports CAPTAIN trial meets primary safety endpoint - Yahoo Finance
Profound Medical's (PROF) TULSA Procedure Shows Superior Safety Outcomes - GuruFocus
Profound Medical Corp. Reports Results of CAPTAIN Trial Comparing MRI-Guided TULSA Procedure to Robotic Radical Prostatectomy - marketscreener.com
CAPTAIN Trial Comparing Profound's MRI-Guided TULSA Procedure to Robotic Radical Prostatectomy Successfully Meets Primary Safety Endpoint, Preservation of Erectile Function and Urinary Continence - Bitget
Profound Medical Trial Shows TULSA Improves Prostate Cancer Outcomes - TipRanks
Profound Medical (PROF) trial: TULSA tops robotic surgery on key safety outcomes - Stock Titan
Prostate trial: MRI-guided TULSA helps more men keep sex and bladder control - Stock Titan
Aug Outlook: What hedge funds are buying Profound Medical Corp2026 Analyst Calls & Risk Controlled Swing Alerts - baoquankhu1.vn
(PRN) Comprehensive Trading Strategy Report (PRN:CA) - Stock Traders Daily
Profound Medical Announces Board Resignation and New Appointment - TipRanks
Medical Co.'s TULSA-PRO Installed Base Growth & CAPTAIN Trial Data Could Accelerate Adoption in 2026 - Streetwise Reports
Profound Medical to Host Investor Call to Discuss First Clinical Outcomes from the CAPTAIN Trial on March 13; Participate in ROTH Investor Conference on March 22-24 - Investing News Network
Profound Medical to Host Investor Call March 13 on First CAPTAIN Trial Outcomes Presented at EAU 2026 - TradingView
Profound Medical (PROF) Awaits Key Clinical Data Presentation - GuruFocus
Profound Medical to Present First CAPTAIN Trial Results and Steps Up Investor Outreach - TipRanks
Profound Medical (NASDAQ: PROF) sets call on CAPTAIN trial data - Stock Titan
(PRN) Technical Pivots with Risk Controls (PRN:CA) - Stock Traders Daily
Profound Medical Corp. (NASDAQ:PROF) Q4 2025 Earnings Call Transcript - Insider Monkey
Profound Medical (TSX:PRN) Narrowing EPS Loss In Q3 2025 Tests Growth Optimism Narrative - simplywall.st
History Review: Can Profound Medical Corp beat the S P 500Market Volume Summary & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Street Watch: Is OVBC forming a bullish divergenceEarnings Performance Report & Verified Swing Trading Watchlist - baoquankhu1.vn
Profound Medical (TSE:PRN) Trading Down 26%Time to Sell? - MarketBeat
Profound Medical reports net loss of USD 8.2M in Q4 2025 - Medical Buyer
Profound Medical (NASDAQ:PROF) Issues Earnings Results - MarketBeat
Profound Medical Corp (PROF) Q4 2025 Earnings Call Highlights: R - GuruFocus
Profound Medical Q4 Earnings Call Highlights - Yahoo Finance
Aug Sentiment: Can Profound Medical Corp beat the S P 500July 2025 Weekly Recap & Stepwise Swing Trade Plans - baoquankhu1.vn
Profound Medical Reports Fourth Quarter and Full Year 2025 Financial Results - Investing News Network
Earnings call transcript: Profound Medical Q4 2025 EPS surprises, stock rises - Investing.com South Africa
Profound Medical (PROF) Reports Q4 Revenue Below Expectations - GuruFocus
Profound Medical (PROF) Reports Q4 Loss, Misses Revenue Estimates - Yahoo Finance
Profound Medical Posts Record Q4 Revenue as TULSA-PRO Adoption and Global Expansion Accelerate - TipRanks
프로파운드 메디컬 (PROF) 재무 분석
매출
순이익
현금흐름
주당 순 이익
프로파운드 메디컬 주식 (PROF) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Menawat Arun Swarup | CEO |
May 15 '25 |
Buy |
4.33 |
10,003 |
43,263 |
575,062 |
자본화:
|
볼륨(24시간):